Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE1625 B · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| AVE1625 B | DRUG | - |
Inclusion Criteria: * Abdominal obese patients with · * Waist circumference \> 102 cm in men and \>88 cm in women * Dyslipidemia consisting of : * Triglycerides ≥ 1.50 g/L (i.e 1.69 mmol/L) and ≤ 7.0 g/L(i.e. 7.90 mmol/L)AND/OR * HDL-cholesterol \< 50 mg/dL (i.e. 1.29 mmol/L) in women and \< 4...
Top 20 of 32 competitors
AVE1625 B is an investigational small molecule being developed for obesity. It was studied in abdominally obese patients with atherogenic dyslipidemia, a condition combining obesity with abnormal blood lipid levels. The drug is in Phase 2 clinical development and is not approved for any use.
AVE1625 B is a small molecule developed by Sanofi. The specific molecular target of AVE1625 B has not been disclosed in available information. It is being investigated for its effects in obesity and dyslipidemia, but the exact mechanism of action is not publicly detailed.
AVE1625 B is developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical research on this investigational drug for the treatment of obesity and related lipid abnormalities.
AVE1625 B is in Phase 2 clinical development. It has completed one Phase 2 trial, and there are no active trials currently listed. The drug remains investigational and has not received regulatory approval for any indication.
AVE1625 B has one completed clinical trial registered under NCT00345410, titled "Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia." This Phase 2 study enrolled 345 participants in the United States and was randomized and double-blind.
AVE1625 B is a designation for the drug also known as AVE1625. The clinical trial NCT00345410 refers to the drug as AVE1625, indicating that AVE1625 B is an alternative name for the same investigational compound developed by Sanofi.